View More Recent Stories
-
Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
BioMarin Pharma (BMRN) Announces New R&D and Business Development Leadership
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Stifel
-
Bernstein SocGen Group Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Outperform
-
Eight defensive growth stocks to own right now
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at TD Cowen
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $112 at Stifel
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at Evercore ISI
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 61c ; Offers Guidance
-
BioMarin Pharma (BMRN) Announces Updated Strategy for ROCTAVIAN to Focus on U.S., Germany and Italy
-
Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
Citi Reiterates Neutral Rating on BioMarin Pharmaceutical Inc. (BMRN)
-
CrowdSrike, KKR, and GoDaddy shares rise after S&P 500 inclusion news

